Table 2 Reasons of temozolomide or temozolomide plus bevacizumab maintenance therapy discontinuation
N = 30 | |
|---|---|
Tumor progression | 10 (33.3%) |
Clinical deterioration without radiological tumor progression | 9 (30.0%) |
Completeion of 12 cycles | 3 (10.0%) |
Complication | 4 (13.3%) |
Changing hospital for palliative care | 4 (13.3%) |